Several new medicines have been found to be more effective than traditional ones used to treat multidrug-resistant tuberculosis (MDR-TB), according to a new international collaborative study led by Dr. Dick Menzies, senior scientist. These findings precipitated a complete overhaul of worldwide TB treatment guidelines, with the results of this work published today in the British medical journal The Lancet.
Approximately 600,000 cases of MDR-TB emerge each year, claiming 240,000 lives. Diagnosis and treatment remains a major challenge with only one in four affected patients being diagnosed and even fewer being treated successfully. Present treatment practices of MDR-TB employ expensive, antiquated drugs that lead to toxic side effects such as constant nausea, hearing loss and renal failure.
Dr. Menzies, who is also a respirologist at the MUHC, and his colleagues combined the data of over 12,000 patients suffering with MDR-TB from 50 studies conducted in 25 countries.
New TB drugs
By compiling such a large amount of data, researchers were able to determine that new TB drugs such as bedaquiline, linezolid, and the later generation fluoroquinolones achieve excellent results in the treatment of MDR-TB, demonstrating consistently better cure rates and reduced mortality compared to currently used treatments.
These new drugs were also effective in treating XDR-TB (extensively drug-resistant TB). In addition, the study showed that daily injections for treating MDR-TB may no longer be necessary (except in the most serious of cases).
The World Health Organization (WHO) has already responded to this study's findings by announcing landmark changes in line with this MDR-TB regimen and, also, positioning fully oral regimens over injectable agents.
"The guidelines committee simply erased the old treatment recommendations and started over. They gave the treatment guidelines a complete make-over," says Dr. Menzies, who is a senior scientist from the Translational Research in Respiratory Diseases Program of the RI-MUHC and a professor of Medicine, and of Epidemiology and Biostatistics at McGill University.
A committee responsible for making recommendations about treatment of MDR-TB with representatives of the American Thoracic Society (ATS), Centres for Disease Control and Prevention (CDC), European Respiratory Society (ERS), and Infectious Disease Society of America (IDSA) have also considered this new information.
"Although these guidelines are not yet finalized, I believe this committee will make similar wholesale changes to the way MDR-TB is treated. Given that each of these new drugs may increase cure rates by as much as 10%, we hope that the new combinations will result in cure rates of up to 90% — which would be extraordinary," says Dr. Menzies.
"The results confirm what TB clinicians around the world are seeing with their own eyes," commented Dr. Paul Farmer of the Department of Global Health and Social Medicine at Harvard University. "It's our hope that after 20 years of recommending these toxic regimens (…) we can finally turn to new and safer therapies based on demonstrably safer and better-tolerated drugs."